PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

Tel-Aviv Sourasky Medical Center40 enrolled

Overview

The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Atherosclerosis

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women over the age of 65 diagnosed with metastatic breast cancer * Men over the age of 65 diagnosed with lung cancer Exclusion Criteria: * Patients under the age of 65 * Patients diagnosed with chronic inflammatory disease or chronic infection * Patients taking steroids and NSAIDS on a regular basis

Locations (1)

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel

Central Contacts

Einat Even Sapir, MD PhD

CONTACT

972-3-6973532 evensap@tasmc.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.